Phase 2, Multiple Ascending Dose Proof of Concept Study

A Phase 2, Randomized, Open-label, Ascending, Sequential Dose Group, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of CMX157 in HBV-infected Subjects

This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels.

This is a phase 2a study to evaluate the safety and tolerability of multiple oral doses of CMX157 at increasing dose levels in hepatitis B virus(HBV) infected subjects.

Inclusion Criteria:

• Capable of giving written informed consent.
• Capable of completing study requirements.
• Chronic hepatitis B positive.
• HBV treatment naïve.

Exclusion Criteria:

• Positive result for HCV(hepatitis C virus), HDV(hepatitis D virus) or HIV(human immunodeficiency virus).
• History or medical condition that could impact patient safety.
• Current or past abuse of alcohol or illicit drugs.
• Abnormal laboratory value or ECG.
• Pregnant or breastfeeding.
• Clinical, histologic or laboratory evidence of significant liver fibrosis or cirrhosis.
• Systemic immunosuppression.
• Received an investigational drug or investigational vaccine within the 90 days prior to the first dose of study drug.